Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03709758
Title Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute

acute myeloid leukemia


Cytarabine + Daunorubicin + Venetoclax

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST